FINDING OF NO SIGNIFICANT IMPACT

Marketing Orders for
Vantage Classic Silver Box, GPC Classic Red 100 Box, Camel Crush Box, Vantage Classic Silver 100 Box, GPC Classic Gold 100 Box, GPC Classic Gold Box, Monarch Classic Gold Box, Monarch Classic Red Box, and Now Menthol Green 100 Soft Pack

Manufactured by R.J. Reynolds Tobacco Company

The Center for Tobacco Products of the Food and Drug Administration (FDA) has carefully considered the potential environmental impacts of these actions and has concluded that these actions will not have significant effects on the quality of the human environment. Therefore, environmental impact statements are not required.

R.J. Reynolds Tobacco Company wishes to introduce nine new combusted, filtered cigarettes into interstate commerce for commercial distribution in the United States and submitted to FDA nine requests for exemption from substantial equivalence to obtain marketing orders under the provisions of section 905(j)(3) of the Federal Food, Drug, and Cosmetic Act.

The Agency prepared the programmatic environmental assessment (PEA), dated February 3, 2020, in accordance with the Council on Environmental Quality's regulations (40 CFR 1500–1508) implementing the National Environmental Policy Act (NEPA) and FDA’s NEPA regulations (21 CFR 25.40) to support the finding of no significant impact. The evidence supporting this finding is contained in the attached PEA, which is available to the public upon request.

The PEA evaluates potential environmental effects due to manufacturing, use, and disposal of the new products. No increased or new types of environmental impacts due to manufacturing the new products are anticipated. The Agency does not foresee that use of the new products would result in new or different environmental impacts. The Agency believes that the disposal of the new products is the same as the disposal conditions of other combusted cigarettes that are currently marketed in the United States. Therefore, the Agency does not foresee adverse impacts to the environment due to the proposed actions as a result of the manufacturing, use, and disposal of the new products.

Digitally signed by Luis G. Valerio -S
Date: 2020.02.03 14:52:24 -05'00'

Approved by
Kimberly Benson, Ph.D.
Director
Division of Nonclinical Science
Office of Science
Center for Tobacco Products
U.S. Food and Drug Administration